Best Open Access Journals In Epigenome Markers|OMICS International|Journal Of Molecular Biomarkers And Diagnosis

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Best Open Access Journals In Epigenome Markers

OMICS Group International through its scholarly open access initiative is committed to make genuine and reliable contributions to the scientific community. It provides the best way to publish the original research work through best open access journals allowing researchers, potential learners and the academic fellow from respective domain to access the same works for free, which also results in quick dissemination of findings and a wide impact. OMICS Group International handles over 700+ peer-reviewed journals through a smooth peer-review process. These journals have over 15 million readers and over 25000 eminent personalities as editorial members to its credit to promote rapid, quality and quick review processing. Alongside OMICS Group Conferences division hosts about 3000+ International Scientific Conferences with numbers steadily growing each year. OMICS Group International had signed agreement with more than 1000+ Scientific associations worldwide to make health care and scientific information open access. Prediction of prostate cancer clinical outcome remains a major challenge after diagnosis. Several high throughput approaches were applied to analyze the genome abnormalities of prostate cancer. To evaluate whether copy number variation (CNV) of genomes in prostate cancer (T), benign prostate tissues adjacent to tumor (AT) and blood of prostate cancer patients predicts biochemical (PSA) relapse and the kinetics of relapse, 241 samples were analyzed through Affymetrix SNP 6.0 chips. Using gene specific CNV from T, the genome model correctly predicted 73% cases for relapse and 75% for short PSADT. The gene specific CNV model from AT correctly predicted 67% cases for relapse and 77% for short PSADT. Using median size of CNV from blood, the genome model correctly predicted 81% for relapse and 69% for short PSADT. To analyzeepigenome abnormalities of prostate cancer, genome wide methylation analyses were performed using both array and whole genome methylation sequencing approaches for 91 human prostate specimens. A gene methylation prediction model was shown to predict prostate cancer relapse with sensitivity of 80.0% and specificity of 85.0%. Through whole genome methylation sequencing, we found both intragene and promoter CpG islands contributed to the suppression of RNA transcription. Most of the differential methylation between T and AT occurred in regions outside the CpG islands. Our analysis indicates that genome or epigenome abnormalities of benign or malignant tissues are predictive of clinical outcome of a malignancy.(JianhuaLuo, Genome and epigenome markers of prostate cancer)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on January, 2021